Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is de... Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. Show more
CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing...
Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); preliminary data expected in 4Q 2024New SPR720...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0693 | -5.13333333333 | 1.35 | 1.37 | 1.24 | 112740 | 1.32079264 | CS |
4 | -0.0793 | -5.83088235294 | 1.36 | 1.42 | 1.24 | 122073 | 1.34427354 | CS |
12 | -0.0393 | -2.97727272727 | 1.32 | 1.53 | 1.15 | 117043 | 1.34063647 | CS |
26 | -0.4293 | -25.1052631579 | 1.71 | 1.81 | 1.15 | 152277 | 1.46400322 | CS |
52 | 0.0607 | 4.97540983607 | 1.22 | 1.89 | 0.99 | 193089 | 1.46619553 | CS |
156 | -17.4693 | -93.1696 | 18.75 | 19.87 | 0.6801 | 963299 | 2.05430478 | CS |
260 | -9.8393 | -88.4829136691 | 11.12 | 23.639 | 0.6801 | 647546 | 3.47633764 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.